Cervical Cancer Deaths Down Following HPV Vaccine Introduction
Reductions in cervical cancer incidence, mortality in the U.S. greater for those aged 15 to 24 years than those aged 25 to 29, 30 to 39 years.
HPV
Cervical Cancer, CIN3 in Young Women Plummeted After HPV Vaccination
Fewer than expected cervical cancers, CIN3 cases seen among vaccinated cohorts after introduction of HPV immunization program in England.
Cutaneous Beta-HPV May Up Risk for Cutaneous Squamous Cell Carcinoma
Cutaneous beta-human papillomavirus (HPV) may predict development of cutaneous squamous cell carcinoma (cuSCC).
HPV Vaccination Rates Low for Young Adults
Rates low for 18- to 21-year-olds reporting vaccination at any age or initiating in young adulthood
HPV Vaccination Rates Suboptimal Within Ages 9 to 12 Years
For most of the study period, higher rates of HPV vaccination initiation and up-to-date rates were seen for non hispanic blacks.
HPV Biomarkers, Survival Linked to High-Grade Esophageal Dysplasia, Adenocarcinoma
Low expression of the HPV-related marker cyclin D1 appears to be an independent prognostic marker in Barrett high-grade dysplasia and esophageal adenocarcinoma.
Many Pelvic Exams, Pap Tests Unnecessary in Teenagers and Young Adults
More than half of bimanual exams, >70 percent of Pap tests in women aged 15 to 20 years unnecessary
Studies Confirm Safety of 9-Valent HPV Vaccination
Studies based on searching Vaccine Adverse Event Reporting System, six Vaccine Safety Datalink sites
Mailing HPV Kits to Underscreened Women Can Increase Screening
No significant difference found in detection of CIN2+ or treatment with intervention versus usual care
One Dose of HPV Vaccine May Be Sufficient in Certain Situations
One dose compared with two or three doses in preventing cervical precancer in high-coverage settings
- Loading...
Loading...
Next post in Prevention
Loading... 
Loading...